HALAVEN (eribulin mesylate) Injection is a non-taxane microtubule dynamics inhibitor. Eribulin mesylate is a synthetic analogue of halichondrin B, a product isolated from the marine sponge Halichondria okadai. The chemical name for eribulin mesylate is 11,15:18,21:24,28-Triepoxy-7,9-ethano12,15-methano-9H,15H-furo[3,2-i]furo[2',3':5,6]pyrano[4,3-b][1,4]dioxacyclopentacosin-5(4H)-one, ... Each vial contains 1 mg of eribulin mesylate as a 0.5 mg/mL solution in ethanol: water (5:95). Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Cost. Eribulin mesylate is available as 1-mg vials for single-use infusion. Since the recommended dose is 1.4 mg/m 2 i.v. on days 1 and 8 of a 21-day cycle, a woman with an average body surface area of 1.7 m 2 would require 2.4 mg per dose, which equates to three vials of eribulin. Eribulin mesylate 1.4-mg/m 2 infusion over 2–5 min on days 1 and 8 of a 21-day cycle. Median overall response rate, 9.3%; median progression-free survival, 2.6 mo; median overall survival, 10.4 mo.
BRAND NAME: Halaven. DRUG CLASS AND MECHANISM: Eribulin mesylate is a chemotherapeutic medicine approved to treat metastatic breast cancer, an advanced form of breast cancer that has spread to other parts of the body. PRESCRIBED FOR: Eribulin is a prescription chemotherapy medicine used to treat patients with metastatic breast cancer. Eribulin should only be used in patients who have already received at least 2 other types of anti-cancer medicines, including an anthracycline and a taxane.
Eribulin mesylate 0.25-, 0.5-, 0.7-, 1-, or 1.4-mg/m 2 infusion on days 1, 8, and 15 of a 21-day cycle. Maximum tolerated dose: 1 mg/m 2. Eribulin mesylate 1.4-mg/m 2 infusion over 2–5 min on days 1 and 8 of a 21-day cycle. Median overall response rate, 9.3%; median progression-free survival, 2.6 mo; median overall survival, 10.4 mo.
2 a b following dosing with eribulin mesylate at or above 0.43 times the recommended human dose (mg/m 2) given once weekly for 3 weeks, or at or above 0.21 times the recommended human dose (mg/m 2) given once weekly for 3 out of 5 weeks, repeated for 6 cycles. The pharmacokinetics (PK) of eribulin is linear with a mean elimination half-life of approximately 40 hours, a mean volume of distribution of 43 L/m 2 to 114 L/m 2 and mean clearance of 1.16 L/hr/m 2 to 2.42 L/hr/m 2 over the dose range of 0.25 mg/m 2 to 4.0 mg/m 2.
What eribulin is. Eribulin is a chemotherapy drug that is a treatment for advanced breast cancer. It is usually used for people who have already had at least two other courses of chemotherapy. Researchers are also looking at eribulin in trials for other cancer types. Eribulin is also called Halaven and its full name is eribulin mesylate. We've listed the side effects associated with eribulin. You can use the links to find out more about each side effect. Where there is no link, please go to our information about cancer drug side effects or use the search box at the top of the page. You may have a few side effects. They may be mild or more severe.
The mesylate salt was approved by the U.S. Food and Drug Administration on November 15, 2010, to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease, including both anthracycline-and taxane-based chemotherapies. Eribulin is also being investigated by Eisai Co. for use in a variety of other solid tumors, including non-small cell lung cancer, prostate cancer and sarcoma. Eribulin is also known as E7389 and ER-086526, and also carries the US NCI designation NSC-707389.
Eribulin Mesylate. listen (er-eh-BYOO-lin MEH-zih-layt). This page contains brief information about eribulin mesylate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. US Brand Name(s). Halaven. FDA Approved. Definition from the NCI Drug Dictionary-Detailed scientific definition and other names for this drug. MedlinePlus Information on Eribulin Mesylate-A lay language summary of important information about this drug that may include the following: 1  warnings about this drug,